VivoSim Labs, INC.

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that develops and operates three-dimensional human tissue models for drug testing and development. The company specializes in liver and intestinal tissue platforms designed to predict drug toxicity, efficacy, and side effect profiles. Its proprietary technologies construct functional 3D human tissues that replicate key aspects of native tissue composition, architecture, and function, including both normal and disease states.

The company generates revenue through multiple service offerings centered on its tissue model platforms. These include hepatic and intestinal toxicology screening, investigational toxicology services, and mechanism of action studies for pharmaceutical and biotechnology clients at various stages of drug development. VivoSim also develops higher-throughput systems and bioprinted tissue models to serve broader research applications across the industry.

Based in San Diego, California, VivoSim operates with a small footprint of 14 full-time employees. The company serves pharmaceutical and biotechnology companies globally, positioning itself as a contract research organization focused on alternative testing methodologies. The company was formerly known as Organovo Holdings, Inc. until rebranding to VivoSim Labs, Inc. in April 2025. It is incorporated in Delaware and trades on Nasdaq.